| Project/Area Number |
15K19601
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
Aoki Yuki 東京医科歯科大学, 医学部附属病院, 非常勤講師 (90706839)
|
|---|
| Research Collaborator |
TAKAGI Masatoshi 東京医科歯科大学, 茨城県小児・周産期地域医療学講座, 准教授 (10406267)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | NSGマウス / 異種移植 / MLL / ALL / DNA修復機構 / ＮＳＧマウス / 乳児白血病 / 疾患モデル / 白血病幹細胞 |
|---|
| Outline of Final Research Achievements |
MLL-rearranged infantile acute lymphocytic leukemia (ALL) is a disease with poor prognosis and establishment of a novel treatment method is desired. We developed a treatment method by drug administration in vivo using a leukemia transplantation model for NSG immunodeficient mouse into which human cells can be transplanted. ALL-derived cell (HAL-01) when transplanted into NSG mouse and treated dose of anthracycline anticancer drug doxorubicin which induces DNA damage, NSG mouse is deficient in Prkdc and disrupted non-homologous end joining (NHEJ), because of its toxicity, he died soon. When cyclosporin, a drug transport pump (p-gp) inhibitor, was used in combination, the survival rate of leukemia transplanted mice was prolonged.
|
